Publication date: Aug 21, 2019
The past 5 years have witnessed the results of many practice-changing studies that have dramatically improved the landscape of adjuvant therapy in patients with resected, high-risk melanoma. After a 20-year era of adjuvant interferon, the anti-CTLA-4 and anti-PD-1 immune-checkpoint inhibitors, and MAPK-directed targeted therapy brought a revolution into the adjuvant treatment of melanoma. These results came along with the practice-changing results of two large multicenter studies showing no benefit in terms of overall survival for completion lymph node dissection after positive sentinel node biopsy. In this review, we summarized the current state of the art of the adjuvant treatment of high-risk melanoma, with a view on future perspectives.
Spagnolo, F., Boutros, A., Tanda, E., and Queirolo, P. The adjuvant treatment revolution for high-risk melanoma patients. 23882. 2019 Semin Cancer Biol.
- New paradigm for stage III melanoma: from surgery to adjuvant treatment.
- Developments in the Management of Stage III Melanoma
- Comparison of seventh and eighth edition of AJCC staging system in melanomas at locoregional stage.
- Trials and Treatment in Advanced Melanoma
- Recurrent amelanotic melanoma of nasal cavity: Biological variability and unpredictable behavior of mucosal melanoma. A case report.